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ABSTRACT
Aortic valve replacement is the second most common
cardiothoracic procedure in the UK. With an ageing
population, there are an increasing number of patients
with prosthetic valves that require follow-up. Imaging
of prosthetic valves is challenging with conventional
echocardiographic techniques making early detection
of valve dysfunction or complications difficult. CT has
recently emerged as a complementary approach
offering excellent spatial resolution and the ability to
identify a range of aortic valve replacement
complications including structural valve dysfunction,
thrombus development, pannus formation and
prosthetic valve infective endocarditis. This review
discusses each and how CT might be incorporated into
a multimodal cardiovascular imaging pathway for the
assessment of aortic valve replacements and in guiding
clinical management.
INTRODUCTION
The utility of cardiac CT for the assessment
of possible aortic valve replacement dysfunc-
tion has risen rapidly over the past 10 years
following a similar, albeit delayed, trajectory
to CT coronary imaging. It can be used to
assess mechanical and bioprosthetic valves
inserted surgically as well valves inserted
using transcutaneous aortic valve implant-
ation (TAVI). Clinicians familiar with both
cardiac CT and valvular heart disease have
identified a number of specific situations
where CT can help in the assessment of pos-
sible aortic valve replacement dysfunction by
providing complementary diagnostic infor-
mation to transthoracic echocardiography,
transoesophageal echocardiography and
cardiac MR. These include the identification
of pannus formation, thrombus, premature
bioprosthetic leaflet degeneration, assess-
ment of bileaflet mechanical valve leaflet
motion and aortic root abscess formation.
While the role of cardiac CT is relatively new
in this setting, its use is steadily expanding
across the world, with many experienced
centres now using it routinely. This article
evaluates the evidence in support of cardiac
CT imaging for the detection of possible
aortic valve replacement dysfunction and
aims to prompt clinicians to consider it in
specific clinical scenarios.
BIOPROSTHETIC AORTIC VALVE
REPLACEMENT DYSFUNCTION
Selecting the appropriate prosthetic heart
valve has traditionally been a difficult deci-
sion for many patients undergoing surgical
aortic valve replacement. However, recent
advances in bioprosthetic valve design,
coupled with an ageing population, have wit-
nessed increasing use of these valves in pref-
erence to metallic valves. With the recent
addition of TAVI, the number of patients
with functioning bioprostheses is only set to
expand further. Surveillance of bioprosthesis
function, looking for evidence of valve
degeneration, forms an integral part of the
long-term management of patients with
these valves and a substantial healthcare
burden.1 This continues to remain relevant
in the modern era where newer generation
bioprosthetic valves offer improved longevity
but still have a limited life span of 10–
15 years. Despite technological advances, bio-
prostheses exhibit more frequent structural
valve dysfunction than mechanical valves
(2.17%/patient-year vs 0%/patient-year,
p=0.0001), resulting in higher rates of repeat
operation (2.32%/patient-year vs 0.62%/
patient-year, p=0.0003).2 The high spatial
and temporal resolution of cardiac CT
makes it well suited to visualise many of the
complications that can arise following bio-
prosthetic valve implantation, namely, struc-
tural valve dysfunction, thrombus
development, pannus formation and pros-
thetic valve infective endocarditis.3 We will
here examine the role of CT in assessing
each of these problems.
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Structural valve dysfunction
Structural valve dysfunction can have catastrophic conse-
quences, yet its underlying pathophysiology remains
incompletely understood. The term structural valve dys-
function encompasses intrinsic functional changes to
the valve leaflets including retraction or tearing, progres-
sive stenosis and disruption of the annular housing or
sewing ring. The principal pathological driver behind
this degeneration and eventual failure appears to be
leaflet calcification. This most commonly results in valvu-
lar regurgitation due to tearing of the leaflets but may
also cause increasing valve stiffness, restenosis and per-
ipheral embolism.4 At the subcellular level, scanning
electron microscopy has revealed that microcrystalline
hydroxyapatite and amorphous calcium phosphate
aggregate into plate-like structures that are incorporated
into the collagen matrix.5 Calcification has been
observed in over half of porcine prosthetic valves
implanted 5 years previously, rising to over three-
quarters of valves aged 8 years or more.6 7 Interestingly
valve calcification and degeneration appears accelerated
in younger patients, perhaps due to increased mechan-
ical stresses in these patients, as highlighted by the fatal
complications following implantation of bovine pericar-
dial bioprostheses in children and young adults.8
Indeed, such is the importance of calcification in struc-
tural valve dysfunction that efforts by valve manufac-
turers aimed at improving longevity have largely focused
on anticalcific strategies including the application of
topical anticalcific agents to the leaflet surfaces.
The mechanisms driving prosthetic valve calcification
are incompletely understood with several different pro-
cesses having been implicated.9 The combination of glu-
taraldehyde pretreatment and an immune rejection
response to residual animal antigens in the bioprosth-
eses leads to the accumulation of extracellular
calcium.10–13 However, recent data have suggested a
third potential mechanism with evidence supporting
prosthetic valve calcification as an active disease process
with many similarities to those observed in aortic sten-
osis and atherosclerosis.13 14 CT is the technique of
choice for imaging macroscopic deposits of calcium in
the vasculature and so potentially allows leaflet calcifica-
tion and degeneration to be identified at an earlier sub-
clinical stage.
While large-scale clinical trials are currently lacking,
the requirement for improved assessment of biopros-
thetic valve calcification was recently illustrated in the
case of severe bioprosthetic valve obstruction in a
13-year-old girl who died suddenly just 23 months after
implantation of a bovine pericardial aortic bioprosth-
esis.8 The rapid deterioration in her valve function
occurred despite recent echocardiography demonstrat-
ing only mildly stenotic gradients and restricted motion
of a single leaflet. Ex vivo CT was performed on this and
two other explanted bioprostheses demonstrating exten-
sive calcification within the central part of the valve leaf-
lets between the aortic and ventricular surfaces.
Immunohistochemistry showed that these calcium
deposits extended along collagen fibres within the
leaflet thereby increasing leaflet thickness. In principle,
calcium is best imaged on non-contrast CT scans, such
as those used for CT calcium scoring of the coronary
arteries and native aortic valves. However, using dedi-
cated software, it is also possible to quantify leaflet calci-
fication on contrast-enhanced cardiac CT, allowing
improved localisation of calcific deposits to the biopros-
thetic leaflets rather than surrounding structures.15 The
challenge is deciding on a suitable threshold for identi-
fying calcium on these scans, although a detection
threshold of 850 Hounsfield units (HU) has recently
been used to identify calcification in native valves that
ultimately goes on to cause clinical complications follow-
ing TAVI.15 Structural components within the prosthesis
such as the stent frame and sewing ring may generate
beam hardening artefact that may obscure or even be
confused with bioprosthetic calcification. An appreci-
ation of the different structural designs of the various
bioprosthetic valves is therefore of use when trying to
identify true structural valve dysfunction.16 While TAVI is
currently reserved for high-risk surgical candidates with
a reduced life expectancy, this procedure is increasingly
used in high-risk younger adults where the long-term
durability of these valves has not been evaluated.
Figure 1 Structural valve degeneration. (A and B) Bioprosthetic aortic valves calcify along the cusp commissures mimicking the
pattern found in native aortic valve disease. (C) Calcified leaflets are reflected onto the sinus walls during transcatheter valve
implantation.
2 Moss AJ, Dweck MR, Dreisbach JG, et al. Open Heart 2016;3:e000494. doi:10.1136/openhrt-2016-000494
Open Heart
group.bmj.com on December 5, 2016 - Published by http://openheart.bmj.com/Downloaded from 
Reports of early TAVI valve degeneration have again
implicated calcification as the key pathological driver,
suggesting that CT may once again be off use in detect-
ing early degeneration. This is supported by several
recent observations. Deutsch and colleagues noted struc-
tural valve dysfunction with several areas of macrocalcifi-
cation on CT in a 4-year-old CoreValve TAVI
bioprosthesis implanted in to a 44-year-old.17 Similar
findings have also been found in elderly patients early
after valve implantation.18 19 Importantly residual
calcium from the original aortic valve around the perim-
eter of the TAVI bioprosthesis must be differentiated
from new calcium formation within the leaflets of the
new prosthetic valve (figure 1).
Reduced leaflet mobility and hypoattenuation leaflet
thickening
One of the major advantages biological prosthetic heart
valves have over mechanical alternatives is the lack of a
requirement for long-term anticoagulant use. During
bioprosthesis endothelialisation, in the first 3 months
after implantation, thrombus formation can occur in
0.8–4.0% of cases.20 However, clinical sequelae of sys-
temic thromboembolism and obstructive thrombosis are
very rare phenomena occurring in 0.9% and 0.03% of
cases, respectively.21 Recent studies performing
contrast-enhanced cardiac CT in TAVI patients have
identified a new phenomenon termed hypoattenuation
leaflet thickening (HALT; figure 2). This was first
described by Pache et al22 in an 86-year-old man with
hypoattenuation of a single prosthetic cusp 7 days after
implantation of a 29 mm SAPIEN XT valve. Subsequent
resolution following coumadin anticoagulation sug-
gested that this finding represented cusp thrombosis
rather than pannus formation. Following this initial
report, three more recent studies have further investi-
gated the frequency and possible clinical significance of
HALT,23–25 and each is discussed below.
Leetmaa et al23 reported the incidence of HALT in a
consecutive cohort of 140 patients undergoing SAPIEN
XT transcatheter aortic valve implantation. Using
prospective-gated cardiac CT, five patients (3.6%) were
found to have hypoattenuating masses on the aortic
surface of the transcatheter valve at 3 months postimplan-
tation. Combined data from the PORTICO IDE study as
well as the RESOLVE and SAVORY registries have sug-
gested a higher incidence of HALT (13–40% of patients)
if scans are performed at earlier time points postimplan-
tation (30 days to 3 months).24 In these pooled registries,
reduced leaflet motion and hypoattenuated lesions were
associated with an increased risk of systemic thrombo-
embolism (3 of 17 patients with these abnormalities vs 1
of 115 patients without; p=0.007), with both features
responding to therapeutic anticoagulation. Ex vivo
Figure 2 (A and B)
Hypoattenuation leaflet thickening
suggestive of thrombus formation
on the supravalvular surface
impinging leaflet motion. (C and
D) Pannus formation underneath
the prosthesis can also restrict
leaflet motion necessitating
surgical removal of the
prosthesis.
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modelling established that changes in mean pressure gra-
dients are dependent on the size of valve and the
number of cusps occluded. This may explain why these
findings on cardiac CT are commonly observed in the
absence of any increase in velocities or pressure gradient
on echocardiography. Indeed at least two cusps must be
involved in a 23 mm PORTICO valve for the effective
orifice area to be sufficiently stenosed to meet current
echocardiographic criteria for detection.26 Early CT
assessment following SAPIEN 3 transcatheter valve
implantation revealed hypoattenuated thickening in
10.3% of patients with a trend towards a higher incidence
in patients administered single-antiplatelet therapy com-
pared with dual-antiplatelet therapy.25 In 13 patients with
hypoattenuated thickening who underwent repeat CT
angiography after 3 months of treatment, all those on a
combination of clopidogrel and phenprocoumon
(WOEST regimen27) had complete resolution of CT
abnormalities. Importantly, there were no thrombo-
embolic or bleeding complications after 8 months of
follow-up.
In light of the asymptomatic presentation of cusp
thrombosis that occurs in spite of dual-antiplatelet
therapy, important questions have been raised regarding
the clinical relevance of hypoattenuated thickening and
whether CT may more appropriately stratify antithrom-
botic therapy following transcatheter valve implantation.
Importantly, the clinical significance of HALT has not
been validated beyond these observational studies and
the recent publication of low 30-day stroke rates follow-
ing TAVI suggests that the presence of this finding does
not always translate into significant thromboembolic
events.28 Randomised control trials are warranted before
recommending routine anticoagulation in a group of
elderly patients that are at high risk of bleeding compli-
cations, although CT may find a role in pinpointing
those patients with most to gain from this therapy.
MECHANICAL AORTIC VALVE REPLACEMENT
DYSFUNCTION
Imaging of mechanical prosthetic valves has traditionally
been performed using transthoracic echocardiography,
transoesophageal echocardiography and fluoroscopy.29 30
Table 1 Differentiating pannus from thrombus on cardiac
CT
Pannus Thrombus
Timing of
presentation
Usually 12 months
after surgery
Occurs at any time
Location Below the aortic
prosthesis
Above or below the
aortic prosthesis
Morphology
on CT
Circular mass
extending from
sewing ring
Contrast
enhancement
Calcification may
be present
Irregularly shaped
mass attached to
leaflet or hingepoint
No contrast
enhancement
CT
attenuation
>145 HU <145 HU
HU, Hounsfield units.
Figure 3 Prosthetic valve
infective endocarditis. (A)
Complications of prosthetic valve
infective endocarditis include the
development of perivalvular
pseudoaneurysm formation
(white asterix). (B) Saccular
pseudoaneurysms (white asterix)
occur in regions where
vegetations (white arrow) erode
through the annulus with a loss of
sewing ring integrity. (C) Bacterial
spread into the aortic root results
in abscess formation (white
asterix). (D) The anatomical
location of erosive shunts (white
arrow) and paravalvular leaks due
to suture dehiscence can be
readily identified using cardiac
CT. LA, left atrium; RA, right
atrium.
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However, the anatomic evaluation of the annular
housing, prosthetic valve leaflets and perivalvular struc-
tures by echocardiography has intrinsic limitations, most
notably the acoustic shadowing artefacts produced by
metallic components of the valve. Although by no
means free of technical limitations, complementary
roles for cardiac CT are emerging in the assessment of
mechanical valves, particularly in acquired mechanical
obstruction and endocarditis. While the metallic compo-
nents of metallic valves also result in artefact on CT,
diagnostic quality images can be obtained in the major-
ity of mechanical valves.
Acquired mechanical prosthetic valve obstruction—
thrombosis and pannus formation
Acquired mechanical prosthetic valve obstruction (PVO)
is an uncommon but serious and potentially fatal
complication of valve replacement.31 A definitive diagno-
sis is of paramount importance due to the associated
morbidity and mortality and the frequent need for
appropriately timed intervention.32 The two main
mechanisms of acquired mechanical PVO are throm-
bosis and pannus formation, both of which restrict
normal leaflet motion.31 Differentiation of these two
causes is of critical importance in guiding appropriate
treatment (table 1). While both can be treated with
urgent surgical revision, valve thrombosis is also poten-
tially amenable to thrombolysis.33 Moreover accurate
assessments of the degree of valve obstruction and the
size of the thrombus will help to determine the urgency
with which intervention is required alongside standard
clinical assessments.31 CT is increasingly being used in
this role to complement standard imaging and to help
guide patient management, in particular when a clear
aetiology has not been established.30
Cardiac CT in suspected acquired mechanical PVO
enables evaluation of leaflet opening and closing angles,
dynamic leaflet motion and the composition of perivalv-
ular masses valve helping to differentiate between valve
thrombosis and pannus formation.33 A recent prospect-
ive trial compared the imaging results from cardiac CT
with post-thrombolysis imaging and/or surgical findings
in patients with acquired mechanical PVO.33 Of the 39
patients with a periprosthetic mass visible on cardiac CT,
thrombus demonstrated a mean attenuation value of 87
(±59 HU) compared with 322 (±122 HU) for pannus.
The investigators recommended a cut-off point of
>145 HU for differentiating pannus from thrombus, pro-
viding a sensitivity of 88% and specificity of 96%.
Additionally, in the patients who underwent thromboly-
sis, those with the lowest attenuation masses demon-
strated the best response to thrombolysis with complete
dissolution in all the <90 HU masses compared with just
42% in the masses with attenuation of between 90 and
145 HU.33
Table 2 The complementary role of CT in the
assessment of aortic valve replacement dysfunction
CT Echocardiography
Prosthetic valve pathology
Calcification +++ +
Pannus ++ +
Thrombus ++ +
Vegetations + +++
Leaflet perforations/tears − +++
Valve dehiscence + +++
Paraprosthetic regurgitation − +++
Aortic root pathology
Perivalvular abscesses +++ ++
Pseudoaneurysm +++ +
Prosthetic valve function + +++
Coronary artery anatomy +++ −
Presurgical planning +++ +
Prevalve-in-valve planning +++ +
Figure 4 Suggested pathway for
assessment of aortic valve
replacement dysfunction.
Transthoracic echocardiography
with follow-on transoesophageal
echocardiography and cardiac CT
provides a detailed functional and
anatomical assessment to guide
further management. AVR, aortic
valve replacement, ViV TAVI,
valve-in-valve transcatheter aortic
valve implantation.
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AORTIC VALVE REPLACEMENT INFECTIVE ENDOCARDITIS
Prosthetic valve infective endocarditis carries a very high
in-hospital mortality rate of 20–40%.34 Transthoracic
echocardiography and transoesophageal echocardiog-
raphy are the front-line investigations in the assessment
of suspected prosthetic valve infection endocarditis;29
however, cardiac CT can prove useful particularly in
cases where echocardiography is inconclusive.32 35
Furthermore, emerging data suggest it can provide
superior detection to echocardiography of several spe-
cific complications including perivalvular abscesses,
pseudoaneurysms, valve dehiscence and extracardiac
foci of infection.35–38 While echocardiography is the
modality of choice for detecting vegetations and valve
dehiscence, the complementary assessment of aortic
root involvement provided by CT improves the diagnos-
tic accuracy for planning surgical intervention (κ statistic
0.66–0.79 for CT or echocardiography alone vs κ statistic
0.88 for combined testing).37
While the temporal resolution of echocardiography
often means that highly mobile vegetations are better
visualised on echocardiography, large prosthetic valve
vegetations can be readily seen on CT as microlobulated,
hypoattenuating lesions attached to the leaflets or
sewing ring.39 If the infection spreads to involve the
sewing ring, suture dehiscence can result in a paravalvu-
lar leak where there is a breach between the inflow and
outflow tract. Loss of the sewing ring integrity leads to
perivalvular pseudoaneurysm formation, which is
evident as a focal, contrast-filled saccular or fusiform
out-pouching arising from the annulus (figure 3).
Extension of infection into the aortic root is more easily
detected using CT compared with transoesophageal
echocardiography and can further inform surgical man-
agement by detecting ancillary features such as pulmon-
ary septic emboli, patency of the coronary arteries,
mediastinal gas and collections.38 Importantly, the add-
ition of CT imaging to standard assessments has been
shown to change the clinical treatment strategy in a
quarter of patients with suspected prosthetic valve infect-
ive endocarditis.35
TECHNICAL CONSIDERATIONS
In 2014, Ghersin et al40 published a suggested protocol
for the CT evaluation of suspected prosthetic valve dys-
function. A retrospective contrast-enhanced cardiac CT
is performed as the primary diagnostic scan for mechan-
ical and bioprosthetic aortic valves. Scans acquired retro-
spectively can be reconstructed to provide images of the
valve at multiple points across the cardiac cycle, allowing
assessment of its open and closed positions, as well as
the visualisation of dynamic motion through systole and
diastole.40 The field of view can be limited to cover the
level of the valve alone (reducing radiation exposure)
or, depending on the clinical indications, expanded to
Figure 5 An example adjunctive
CT imaging in the management
of aortic valve replacement
dysfunction. (A) Severe
prosthesis regurgitation on
transoesophageal
echocardiography resulted from
calcific structural valve
dysfunction of the bioprosthetic
leaflets in a 27 mm Aspire
bioprosthesis demonstrated on
CT (B). (C and D) Preprocedural
planning facilitated implantation of
a transcatheter aortic valve in
valve.
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cover other areas of interest, including the coronary
arteries.
Multiple factors can affect image quality when asses-
sing mechanical aortic valve prostheses using CT, in par-
ticular the presence of cardiac arrhythmia and older
prosthetic valve types.41 Anecdotal evidence suggests that
modern low profile bileaflet mechanical valves can be
imaged with diagnostic certainty by cardiac CT with
minimal beam hardening artefacts. Postprocessing tech-
niques support the assessment of mechanical aortic
valve leaflet opening and closing angles, limitation of
leaflet motion and the presence or absence of peripros-
thetic pannus.41 The presence of a concurrent pros-
thetic mitral valve and variations in tube voltage ranging
from 80 to 140 kV does not have a discernable affect on
image quality.41 Minimising radiation dose while main-
taining diagnostic quality images can be achieved with
tube current modulation and the use of 100 kV tube
potential in patients with a body mass index under
30 kg/m2.40
Based on current practice in experienced valve
centres, we suggest that CT should be performed as an
anatomical assessment following transthoracic echocardi-
ography in patients with suspected prosthetic aortic
valve dysfunction (table 2, figures 4 and 5). The detailed
structural assessment afforded by cardiac CT more
accurately identifies the underlying pathology and facili-
tates the implementation of appropriate aortic valve
intervention.
CONCLUSION
The diagnosis and management of aortic valve replace-
ment dysfunction remains a significant clinical chal-
lenge. Cardiac CT provides complementary assessments
of these valves allowing detection of structural dysfunc-
tion, leaflet calcification, thickening, thrombus and
pannus formation. This can help to stratify downstream
management and clinical decision-making as part of
multimodality imaging approach.
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